Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles - PubMed (original) (raw)
. 2004 May 1;109(5):759-67.
doi: 10.1002/ijc.20048.
Affiliations
- PMID: 14999786
- DOI: 10.1002/ijc.20048
Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles
Sebastian C J Steiniger et al. Int J Cancer. 2004.
Abstract
Glioblastomas belong to the most aggressive human cancers with short survival times. Due to the blood-brain barrier, they are mostly inaccessible to traditional chemotherapy. We have recently shown that doxorubicin bound to polysorbate-coated nanoparticles crossed the intact blood-brain barrier, thus reaching therapeutic concentrations in the brain. Here, we investigated the therapeutic potential of this formulation of doxorubicin in vivo using an animal model created by implantation of 101/8 glioblastoma tumor in rat brains. Groups of 5-8 glioblastoma-bearing rats (total n = 151) were subjected to 3 cycles of 1.5-2.5 mg/kg body weight of doxorubicin in different formulations, including doxorubicin bound to polysorbate-coated nanoparticles. The animals were analyzed for survival (% median increase of survival time, Kaplan-Meier). Preliminary histology including immunocytochemistry (glial fibrillary acidic protein, ezrin, proliferation and apoptosis) was also performed. Rats treated with doxorubicin bound to polysorbate-coated nanoparticles had significantly higher survival times compared with all other groups. Over 20% of the animals in this group showed a long-term remission. Preliminary histology confirmed lower tumor sizes and lower values for proliferation and apoptosis in this group. All groups of animals treated with polysorbate-containing formulations also had a slight inflammatory reaction to the tumor. There was no indication of neurotoxicity. Additionally, binding to nanoparticles may reduce the systemic toxicity of doxorubicin. This study showed that therapy with doxorubicin bound to nanoparticles offers a therapeutic potential for the treatment of human glioblastoma.
Copyright 2004 Wiley-Liss, Inc.
Similar articles
- Treatment of glioblastoma with poly(isohexyl cyanoacrylate) nanoparticles.
Wohlfart S, Khalansky AS, Bernreuther C, Michaelis M, Cinatl J Jr, Glatzel M, Kreuter J. Wohlfart S, et al. Int J Pharm. 2011 Aug 30;415(1-2):244-51. doi: 10.1016/j.ijpharm.2011.05.046. Epub 2011 May 27. Int J Pharm. 2011. PMID: 21641983 - Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model.
Ambruosi A, Gelperina S, Khalansky A, Tanski S, Theisen A, Kreuter J. Ambruosi A, et al. J Microencapsul. 2006 Aug;23(5):582-92. doi: 10.1080/02652040600788080. J Microencapsul. 2006. PMID: 16980278 - Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants.
Petri B, Bootz A, Khalansky A, Hekmatara T, Müller R, Uhl R, Kreuter J, Gelperina S. Petri B, et al. J Control Release. 2007 Jan 22;117(1):51-8. doi: 10.1016/j.jconrel.2006.10.015. Epub 2006 Oct 21. J Control Release. 2007. PMID: 17150277 - Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma.
Gelperina SE, Khalansky AS, Skidan IN, Smirnova ZS, Bobruskin AI, Severin SE, Turowski B, Zanella FE, Kreuter J. Gelperina SE, et al. Toxicol Lett. 2002 Jan 25;126(2):131-41. doi: 10.1016/s0378-4274(01)00456-8. Toxicol Lett. 2002. PMID: 11751017 - Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE. van Tellingen O, et al. Drug Resist Updat. 2015 Mar;19:1-12. doi: 10.1016/j.drup.2015.02.002. Epub 2015 Mar 6. Drug Resist Updat. 2015. PMID: 25791797 Review.
Cited by
- New applications of nanotechnology for neuroimaging.
Suffredini G, East JE, Levy LM. Suffredini G, et al. AJNR Am J Neuroradiol. 2014 Jul;35(7):1246-53. doi: 10.3174/ajnr.A3543. Epub 2013 Mar 28. AJNR Am J Neuroradiol. 2014. PMID: 23538408 Free PMC article. - Assessment of the Blood Parameters, Cardiac and Liver Enzymes in Oral Squamous Cell Carcinoma Following Treated with Injectable Doxorubicin-Loaded Nano-Particles.
Moradzadeh Khiavi M, Anvari E, Hamishehkar H, Abdal K. Moradzadeh Khiavi M, et al. Asian Pac J Cancer Prev. 2019 Jul 1;20(7):1973-1977. doi: 10.31557/APJCP.2019.20.7.1973. Asian Pac J Cancer Prev. 2019. PMID: 31350953 Free PMC article. - Nanotechnology-based drug delivery systems.
Suri SS, Fenniri H, Singh B. Suri SS, et al. J Occup Med Toxicol. 2007 Dec 1;2:16. doi: 10.1186/1745-6673-2-16. J Occup Med Toxicol. 2007. PMID: 18053152 Free PMC article. - Nanocarriers' entry into the cell: relevance to drug delivery.
Hillaireau H, Couvreur P. Hillaireau H, et al. Cell Mol Life Sci. 2009 Sep;66(17):2873-96. doi: 10.1007/s00018-009-0053-z. Epub 2009 Jun 5. Cell Mol Life Sci. 2009. PMID: 19499185 Free PMC article. Review. - Nanocarrier-based drug combination therapy for glioblastoma.
Zhao M, van Straten D, Broekman MLD, Préat V, Schiffelers RM. Zhao M, et al. Theranostics. 2020 Jan 1;10(3):1355-1372. doi: 10.7150/thno.38147. eCollection 2020. Theranostics. 2020. PMID: 31938069 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical